December 19, 2025
avatar-torie-bosch
First Opinion editor

An evangelical Christian, a Jew, and an agnostic walked into a podcast …

On the final episode of this season of the “First Opinion Podcast,” I spoke with former NIH Director Francis Collins and Fox News senior medical analyst Marc Siegel, author of the new book “The Miracles Among Us,” about the intersection of faith, science, and medicine. Collins, who became an evangelical Christian in his 20s, spoke eloquently about how he sees science as a way to get closer to God, even “glimpsing God’s mind,” as he described his word decoding the human genome.

We also talked about the way many people of faith have become anti-vaccine and anti-science more broadly.

I’m an agnostic — some might call me a Cashew, as my mother was Catholic and my father Jewish — and found the conversation illuminating and even a bit hopeful.

The podcast will be back in the spring. Let me know who you’d like to hear on the show.

Also: This is the last newsletter of 2025. I wish you and your families happy holidays. Thank you so much for reading First Opinion.

And if you’re still shopping for a gift for a loved one or for yourself — well, how about the gift of rigorous, thoughtful, fair reporting on the most important topics in medicine? Get 25% off your first year of STAT+. The offer ends Tuesday.

Recommendation of the week: “Wild Dark Shore,” by Charlotte McConaghy, plays out on a frigid but warming island located between Australia and Antarctica that houses a seedbank under threat from climate change. A family of caretakers on the island is shocked when a mysterious woman washes ashore, and personal dramas intersect with an impossible question: How do you decide what seeds to save and what to let drown?



Adobe

Siddhartha Mukherjee: Metabolism is the next frontier in cancer treatment

It’s time to move on from one-size-fits-all “cancer diets” and move instead to tumor-informed metabolism, writes Siddhartha Mukherjee.

By Siddhartha Mukherjee


STAT+ | I’m the former head of Pfizer R&D. I’m very worried about biopharma’s future

Changes at the FDA are going to have a profound impact on drug development, hurting both patients and the industry.

By John L. LaMattina


Why Denmark’s vaccine schedule works for Denmark — but not for the United States

When it comes to vaccines, Denmark and the U.S. have fundamentally different health care systems, disease burdens, and policy priorities.

By Jake Scott


William Scott/Library of Congress

5 lessons for U.S. research funding from the AIDS crisis

In the ’80s, AIDS researchers didn’t wait for Washington for funding. Today’s scientists must do the same.

By Robert B. Shpiner


What I’ve learned by mapping the impacts of NIH cuts

Measuring and communicating emerging threats to science and medical research is now more essential than ever.

By Joshua S. Weitz


New York Giants team doctor: Clinics offering ‘miracle injections,’ ‘next generation cell therapies’ are selling false hope

Football players, like many desperate to stay healthy or young, are falling prey to regenerative medicine scams, writes the Giants team doctor.

By Scott Rodeo


Karen Ducey/Getty Images

U.S. scientists must compete internationally, just like auto and steel workers do

At the peak of the scientific career pyramid, U.S. scientists are sheltered from foreign competition when applying for research funding.

By Mikko Packalen


Francis Collins and Marc Siegel say medicine is a gift from God

Rather than seeing religion and science as separate spheres, Francis Collins and Marc Siegel believe they are intertwined.

By Torie Bosch


New gonorrhea drug is not just a scientific breakthrough but a business one

The new antibiotic zoliflodacin for gonorrhea was developed by a revolutionary not-for-profit R&D model.

By Manica Balasegaram


A National Institutes of Health building under construction in 1938 in Bethesda, Md.
NIH

Where does the NIH go from here?

Americans largely agree that the federal government should dedicate resources to the NIH. What does that look like?

By Christopher M. Worsham and Anupam B. Jena


We crunched the numbers on drug discovery in the U.S. vs. China. The results were alarming

Federal policy and priorities are kneecapping the historical American engines of innovation, to China’s benefit.

By Michael Kinch and Kevin Gardner


My patient was gone. I had to help his family see it

Machines sustain the appearance of life, even when the person is already gone. I had to help my patient's family understand.

By Raya Elfadel Kheirbek


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying First Opinion? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.